ASCO 2017 Meeting Summary: Updates to Practice-Changing Studies in Untreated Non-Hodgkin Lymphoma

P Laneuville,A Christofides,J.F Larouche,A Tosikyan

doi:10.3747/co.24.3797

Abstract

The 2017 annual meeting of the American Society of Clinical Oncology took place in Chicago, Illinois, 2–6 June. At the meeting, results from key studies in the first-line treatment of indolent non-Hodgkin lymphoma (iNHL) were presented. Of those studies, two were selected for oral presentations: 9-year follow-up data from the STiL NHL1 trial, which compared the efficacy and safety of bendamustine plus rituximab (BR) with those of rituximab plus cyclophosphamide–vincristine–prednisone–doxorubicin (R-CHOP); and 5-year follow-up data from the bright study, which compared BR with R-CHOP and R-CVP (rituximab plus cyclophosphamide–vincristine–prednisone) combined. Our meeting report describes the foregoing studies and includes interviews with key investigators, plus commentaries from three Quebec hematologists on the potential effects for Canadian practice.

Highlights

The current standard of care in Canada for the first-line treatment of indolent non-Hodgkin lymphoma is bendamustine in combination with rituximab, followed by rituximab maintenance[1]
Compared with patients having a Follicular Lymphoma International Prognostic Index score of 3–5, those with a score of 0–2 experienced a significant improvement in os
The trial had a clean and straightforward design to compare the two treatment regimens, because it was not influenced by rituximab maintenance or consolidating transplantation

Summary

Introduction

The current standard of care in Canada for the first-line treatment of indolent non-Hodgkin lymphoma (inhl) is bendamustine in combination with rituximab (br), followed by rituximab maintenance[1]. Before the acceptance of br as the standard regimen in this setting, rituximab with either cyclophosphamide–vincristine–prednisone– doxorubicin (r-chop) or cyclophosphamide–vincristine– prednisone (r-cvp) was given as first-line therapy. R-chop was given in preference to r-cvp elsewhere in the world, especially once the results of a study by Federico et al.[2] demonstrated superior 3-year progression-free survival (pfs) for r-chop compared with r-cvp (p < 0.05). The shift in treatment from r-chop or r-cvp to br was based largely on initial results from the phase iii Study Group Indolent Lymphomas (stil) nhl[1] trial, published in

Objectives

Methods

Results

Conclusion